Retatrutide Phase 3 TRIUMPH-1: 28.3% Weight Loss at 80 Weeks

On June 6, 2026, at the ADA Scientific Sessions in New Orleans, Phase 3 TRIUMPH1 results established retatrutide as the most efficacious pharmacological obesity agent ever reported in a Phase 3 setting. Participants on the 12 mg dose achieved 28.3% average body weight reduction at 80 weeks — with 33.3% reaching a healthy BMI below 25. Here is the complete dataset.

For research use only. Not for human consumption.